

DAFTAR PUSTAKA

1. Nurdjanah S, Sirosis Hati. di: Setiati S, Alwi I, Sudoyo AW, Setiyohadi B, Syam AF, editor. Buku Ajar Ilmu Penyakit Dalam (6th ed). Jakarta: Interna Publishing; 2014. p. 1978-83.
2. Virma SG, Adelin P, Mona L. Karakteristik Pasien Sirosis Hepatis di Rumah Sakit Dr. Achmad Mochtar Bukittinggi Periode Tahun 2018 - 2020. Jurnal Kedokteran Nanggroe Medika. 2023;6(1):1-7
3. Lovena A, Miro S, Efrida E. Karakteristik Pasien Sirosis Hepatis di RSUP Dr. M. Djamil Padang. J Kesehat Andalas. 2017;6(1):5.
4. Nusi IA, Maimunah U, Fibrosis dan Sirosis Hati. di: Setiati S, Alwi I, Sudoyo AW, Setiyohadi B, Syam AF, editor. Buku Ajar Ilmu Penyakit Dalam (7th ed). Jakarta: Interna Publishing; 2024. p. 2268-74.
5. Ebrahimi H, Naderian M, Sohrabpour AA. New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article. Middle East J Dig Dis. 2016;8(3):166–178.
6. Shen X, Cheng S, Peng Y, Song H, Li H. Attenuation of early liver fibrosis by herbal compound “Diwu Yanggan” through modulating the balance between epithelial-to-mesenchymal transition and mesenchymal-to-epithelial transition. BMC Complement Altern Med. 2014;14:418.
7. El-Hariri M, Abd El Megid AG, Taha Ali TF, Hassany M. Diagnostic value of Transient Elastography (Fibroscan) in the evaluation of liver fibrosis in chronic viral hepatitis C: Comparison to liver biopsy. Egypt J Radiol Nucl Med. 2017;48(2):329–37.
8. Kotak PS, Kumar J, Kumar S, Varma A, Acharya S. Navigating Cirrhosis: A Comprehensive Review of Liver Scoring Systems for Diagnosis and Prognosis. Cureus. 2024;16(3): 1-9.
9. Liu D, Chen J, Wang J, Zhang z. Increased expression of urotensin II and GPR14 in patients with cirrhosis and portal hypertension. International Journal Of Molecular Medicine. 2010;25(6):845-51.

10. McDonald J, Batuwangala M, Lambert DG. Role of urotensin II and its receptor in health and disease. *J Anesth*. 2007;21(3):378–89.
11. Liang DY, Hou YQ, Lou XL. Progress in understanding role of urotensin II in hepatic cirrhosis. *World Chinese Journal of Digestology*. 2013;21(22):2164-8.
12. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, A M Romanic AM, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. *Nature*. 1999;401(6750):282-6.
13. Kemp W, Krum H, Colman J, Bailey M, Yandle T, Richards M, et al. Urotensin II: a novel vasoactive mediator linked to chronic liver disease and portal hypertension. *Liver Int*. 2007;27(9):1232-9.
14. Zheng X, Wang L, He J. Diagnostic value of serum cystatin C and urotensin II for hepatorenal syndrome in patients with decompensated liver cirrhosis. *J Clin Hepatol*. 2013;29(8):628–32.
15. Metwally K, Naguib MA, Saeedc M, El-Azab G, Assema M. Urotensin II as a novel marker for portal hypertension and bleeding varices: an Egyptian survey. *Egyptian Liver Journal*. 2015; 5(3):54-9.
16. Aydin F, Cindoglu C, Kirhan I, Uyanikoglu A, Yenice N. Serum prolidase, urotensin II and nesfatin levels in patients with compensated or uncompensated cirrhosis. *Annals of Medical Research*. 2019;26(8):1666-9.
17. Clirncey CI, Goldberg EM, Chopra S. Cirrhosis and portal hypertension: an overview. In: Friedman LS and Keefe EB, editor. *Handbook of Liver Disease*. 2nd ed. China : Churchill Livingstone; 2014. p. 125–38.
18. Mokdad AA, Lopez AD, Shahrzaz S, Lozano R, Mokdad AH, Stanaway J, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. *BMC Med*. 2014;12(1):145.
19. Hadi S. *Gastroenterologi*. 7th ed. Bandung: P.T. Alumni; 2013. p. 613–620.
20. Patasik YZ, Waleleng BJ, Wantania F. Profil pasien sirosis hati yang dirawat inap di RSUP Prof. Dr. D. Kandou Manado periode Agustus 2012 sampai Agustus 2014. *Eclinic*. 2015;3(1):342-7.

21. Afifah I, Sopiany HM. Hubungan Nilai Prothrombin Time dan Albumin Dengan Staging Pasien Sirosis Hepatis di RSUP DR. Wahidin Sudirohusodo Makassar Periode Januari - Desember 2016. 2017;87(1,2):149–200.
22. Tambunan A, Mulyadi Y, Kahtan MI. Karakteristik pasien sirosis hati di RSUP Dr. Soedarso Pontianak periode Januari 2008 - Desember 2010. Jurnal Mahasiswa PSPD FK Universitas Tanjungpura. 2013;2(1):1-19.
23. Maharani S. Gambaran Pemeriksaan Fungsi Hati pada Pasien Sirosis Hepatis yang Dirawat di Rumah Sakit Umum Daerah Arifin Achmad Provinsi Riau Periode 2013 - 2015. JIK. 2018;12(1):1–4.
24. Wiegand J, Berg T. The Etiology, Diagnosis and Prevention of Liver Cirrhosis. *Deutsches Ärzteblatt International*. 2013;110(6):85–91.
25. Brenner DA. Molecular pathogenesis of liver fibrosis. *Trans Am Clin Climatol Assoc*. 2009;120:361–8.
26. Suk KT, Kim DJ. Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure gradient measurement. *World J Hepatol*. 2015;7(3):607–615.
27. Tapper EB, Parikh ND. Diagnosis and Management of Cirrhosis and Its Complications A Review. *JAMA*. 2023;329(18):1589-1602.
28. Jagdish RK, Roy A, Kumar K, Premkumar M, Sharma M, Rao PN, et al. Pathophysiology and management of liver cirrhosis: from portal hypertension to acute-on-chronic liver failure. *Front Med*. 2023;10(1):1-11.
29. Lindseth GN. Gangguan Hati, Kandung Empedu dan Pankreas. di : Price SA, Wilson LM, editor. *Patofisiologi* (6th ed). Jakarta: EGC; 2012.
30. Peng Y, Qi X, Guo X. Child–Pugh versus MELD score for the assessment of prognosis in liver cirrhosis: a systematic review and meta-analysis of observational studies. *Medicine (Baltimore)*. 2016;95(8):1-29.
31. Del Poggio P, Colombo S. Is transient elastography a useful tool for screening liver disease?. *World J Gastroenterol* . 2009;15(12):1409-14.
32. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. *J Hepatol*. 2008;48(5):835–47.

33. Yu JH, Lee JI. Current role of transient elastography in the management of chronic hepatitis B patients. *Ultrasonography*. 2017;36(2):86-94.
34. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. *J Hepatol*. 2008;48(5):835-47.
35. Ferraioli G, Filice C, Castera L, Choi BI, Sporea I, Wilson SR, et al. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: Liver. *Ultrasound in Medicine & Biology*. 2015;41(5):1161 – 78.
36. Proulx CD, Holleran BJ, Lavigne P, Escher E. Biological properties and functional determinants of the urotensin II receptor. *Peptides*. 2008;29(5):691-9.
37. Ross B, McKendy, Giaid A. Role of urotensin II in health and disease. *Am J Physiol Regul Integr Comp Physiol*. 2010;298(5):1156-72.
38. Heller J, Schepke M, Neef M, Woitas R, Rabe C, Sauerbruch T. Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. *J Hepatol*. 2002;37(6):767-72.
39. Charles CJ, Rademaker MT, Richards AM, Yandle TG. Urotensin II: evidence for cardiac, hepatic and renal production. *Peptides*. 2005;26(11):2211-4.
40. Kemp W, Krum H, Colman J, Bailey M, Richards SR. Serum urotensin II elevation in chronic liver disease-relationship to severity of cirrhosis and portal hypertension. *J Gastro Hepatol*. 2005; 20(1): 86.
41. Balat A, Buyukcelik M. Urotensin-II: More Than a Mediator for Kidney. *Int J Nephrol*. 2012;2012:1-7.
42. Liu DG, Wang J, Zhang ZT, Wang Y. The urotensin II antagonist SB-710411 arrests fibrosis in CCL4 cirrhotic rats. *Mol Med Rep*. 2009;2(6):953-61.
43. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F, et al. Direct actions of urotensin II on the heart: Implications for cardiac fibrosis and hypertrophy. *Circ Res*. 2003;93(3):246-53.

44. Patacchini R, Santicioli P, Giuliani S, Grieco P, Novellino E, Rovero P, et al. The Urotensin II receptor. di : Michel MC, editor. Handbook of Experimental Pharmacology. Berlin, Heidelberg: Springer; 2003.
45. Maguire JJ, Kuc RE, Davenport AP. Vascular reactivity to urotensin II in human and rat vessels in vitro: evidence for species differences and the role of endothelin. *Br J Pharmacol*. 2000;131(3):441-4.
46. Behm DJ, Herold CL, Ohlstein EH, Douglas SA. SB-710411: the first selective, non-peptide antagonist of the urotensin-II receptor. *Br J Pharmacol*. 2002;137(3):335-42.
47. Kemp W, Roberts S, Krum H, Lubel J, Herath C, Bellomo R, et al. The role of the urotensin II receptor in the development of portal hypertension. *Hepatology*. 2004;40(2):358-66.
48. Charles CJ, Rademaker MT, Richards AM, Yandle TG. Urotensin II: Evidence for cardiac, hepatic and renal production. *Peptides*. 2005;26(11):2211-4.
49. Chen YH, Yandle TG, Richards AM, Palmer SC. Urotensin II immunoreactivity in the human circulation: evidence for widespread tissue release. *Clin Chem*. 2009;55(11):2040-8.
50. Kemp W, Roberts S, Krum H. Increased circulating urotensin II in cirrhosis: potential implications in liver disease. *Peptides* . 2008;29(5):868-72.
51. Rex DAB, Suchitha GP, Palollathil A, Kanichery A, Prasad TSK, Dagamajalu S. The network map of urotensin-II mediated signaling pathway in physiological and pathological conditions. *J Cell Commun Signal*. 2022;16(6):601–608.
52. Ignat SR, Dinescu S, Hermeheean A, Costache M. Cellular interplay as a consequence of inflammatory signals leading to liver fibrosis development. *Cells*. 2020;9(2):461.
53. Liu LM, Liang DY, Ye CG, Tu WJ, Zhu T. The UII/UT system mediates upregulation of proinflammatory cytokines through p38 MAPK and NF- κ B pathways in LPS-stimulated Kupffer cells. *PLoS One*. 2015;10(3):1-13.

54. Liang DY, Liu LM, Ye CG, Zhao L, Yu FP, Gao DY, et al. Inhibition of UII/UTR system relieves acute inflammation of liver through preventing activation of NF- κ B pathway in ALF mice. *PLoS One*. 2014;8(6):1-9.
55. Sun SL, Liu LM. Urotensin II: an inflammatory cytokine. *J Endocrinol*. 2019;240(3):107–117.
56. Leifeld L, Clemens C, Heller J, Trebicka J, Sauerbruch T, Spengler U. Expression of urotensin II and its receptor in human liver cirrhosis and fulminant hepatic failure. *Dig Dis Sci*. 2010;55(5):1458-64.
57. Pomier-Layrargues G, Paquin SC, Hassoun Z, Lafortune M, Tran A. Octreotide in hepatorenal syndrome: a randomized, double-blind, placebo-controlled, crossover study. *Hepatology*. 2003;38(1):238-43.
58. Trebicka J, Leifeld L, Hennenberg M, Biecker E, Eckhardt A, Fischer N et al. Hemodynamic effects of urotensin II and its specific receptor antagonist palosuran in cirrhotic rats. *Hepatology*. 2008;47(4):1264-76.
59. Zhong H, He Y, Yang X, Si QQ, Xie P, Gao DY, et al. Liver injury mediated by the UII and its receptor (UT) system is possibly associated with the activation of autophagy-related and apoptosis-resisted pathways of Kupffer cells in acute liver failure. *European Journal of Inflammation*. 2021;19(4):1-11.
60. Cui H, Lin Y, Xie L, Zhao J. Urantide decreases hepatic steatosis in rats with experimental atherosclerosis via the MAPK/Erk/JNK pathway. *Mol Med Rep*. 2021;23(4):284.
61. Suguro T, Watanabe T, Ban Y. Association of Urotensin II and its receptor with insulin resistance and type 2 diabetes in the Japanese. *Diabetes*. 2004;53(12):2813–2820.
62. Arianti R, Ariani NL, Muhammad AA, Sadewa AH, Farmawati A, Sunarti, et al. Influence of Single Nucleotide Polymorphism of ENPP1 and ADIPOQ on Insulin Resistance and Obesity: A Case-Control Study in a Javanese Population. *Life (Basel)*. 2021;11(6):552.

63. Sajorda J, Gerstein HC, Kotalik Z, Mohammadi-Shemirani P, Pigeyre M, Hess S, et al. Influence of genetic ancestry on human serum proteome. *Am J Hum Genet.* 2020;106(3):303–14.

